Review Article

Systemic Mastocytosis: Molecular Landscape and Implications for Treatment

Cecilia Monaldi*1, Sara De Santis1, Manuela Mancini2, Samantha Bruno1, Michele Cavo1,2 and Simona Soverini1.

1 Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy.
2 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy.

Competing interests: The authors declare no conflict of Interest.

Abstract. Over the past decade, we have witnessed significant advances in the molecular characterization of systemic mastocytosis (SM). This has provided important information for a better understanding of the pathogenesis of the disease but has also practically impacted the way we diagnose and manage it. Advances in molecular testing have run in parallel with advances in therapeutic targeting of constitutive active KIT, the major driver of the disease. Therefore, assessing the molecular landscape in each SM patient is essential for diagnosis, prognosis, treatment, and therapeutic efficacy monitoring. This is facilitated by the routine availability of novel technologies like digital PCR and NGS. This review aims to summarize the pathogenesis of the disease, discuss the value of molecular diagnostic testing and how it should be performed, and provide an overview of present and future therapeutic concepts based on fine molecular characterization of SM patients.

Keywords: Systemic mastocytosis; KIT; Allele burden; Tyrosine kinase inhibitor.

Citation: Monaldi C., De Santis S., Mancini M., Bruno S., Cavo M., Soverini S. Systemic mastocytosis: molecular landscape and implications for treatment. Mediterr J Hematol Infect Dis 2021, 13(1): e2021046, DOI: http://dx.doi.org/10.4084/MJHID.2021.046

Published: July 1, 2021 Received: May 26, 2021 Accepted: June 11, 2021

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Correspondence to: Cecilia Monaldi, PhD student. Institute of Hematology “L. e A. Seràgnoli”, Via Massarenti 9, 40138 Bologna, Italy. Tel: +390512143791. E-mail: cecilia.monaldi2@unibo.it

Introduction. Mastocytosis is a rare neoplasm characterized by the expansion and accumulation in different organs/tissues of clonal mast cells (MCs) that can be recognized as morphologically and immunophenotypically abnormal.1 The clinical presentation of mastocytosis is heterogeneous, with various manifestations ranging from skin-limited disease (cutaneous mastocytosis, CM) to extra-cutaneous involvement (systemic mastocytosis, SM). CM is frequent in the pediatric age but it can spontaneously regress during puberty.2,3 In contrast, SM is generally seen in adult patients and may be associated with multiorgan dysfunction and shortened survival.4 The 2016 World Health Organization (WHO) defined major categories and variants of SM. Based on histological criteria, clinical parameters, and organ involvement, SM is divided into indolent SM (ISM), smoldering SM (SSM), and advanced SM variants (AdvSM), including SM with an associated clonal hematopoietic non-MC disease (SM-AHN), aggressive SM (ASM) and MC leukemia (MCL).5 ISM is the most common subtype and has a relatively benign prognosis,6 although 5 to 10% of ISM patients progress to SSM or AdvSM.7,8 SSM is associated with an increased symptom burden, inferior survival compared to ISM, and a much higher transformation rate (15-20% for transformation to AdvSM or acute leukemia).9 In addition, patients with AdvSM have a reduced life expectancy.10 Whereas treatment of ISM is generally palliative and primarily directed towards preventing anaphylaxis and the control of symptoms, treatment of AdvSM needs cytoreductive therapy to ameliorate disease-related organ dysfunction. For a long time, high-dose chemotherapy possibly followed by transplant when
feasible, interferon or cladribine have represented the main options for AdvSM patients. The knowledge of the driver lesion underlying the molecular pathogenesis of SM has ultimately enabled the development of targeted therapies. Despite the great hurdle represented by the rarity of AdvSM patients, the tyrosine kinase inhibitor midostaurin has recently been approved based on the results of phase 2 clinical trial that lasted almost 10 years. Other investigational agents, like avapritinib and ripretinib, are being evaluated. In addition, several additional compounds with the same or even different targets have been tested at the preclinical level.

In this review, we summarize the molecular studies and acquisitions that have led to a better understanding of the pathogenesis of SM, paving the way to the development of targeted therapies. Moreover, we discuss how the implementation of advanced molecular technologies has recently refined the diagnostic and prognostic algorithms and how molecular testing is acquiring a pivotal role in treatment individualization. Finally, we also provide an overview of a series of new putative therapeutic targets, some of whom might find a clinical translation, primarily via repurposing of already approved agents.

Activating KIT Mutations Drive the Pathogenesis of SM. SM is virtually always associated with somatic gain-of-function mutations of the proto-oncogene c-KIT, which encodes a transmembrane protein belonging to type III tyrosine kinase receptors. KIT is expressed by MCs, hematopoietic progenitor cells, germ cells, melanocytes, and interstitial cells of Cajal in the gastrointestinal tract. KIT expression is downregulated upon differentiation of hematopoietic progenitors into mature cells of all lineages, except in MCs that retain high cell surface KIT expression levels. The KIT receptor explicitly binds the stem cell factor (SCF) cytokine, also known as the KIT ligand, steel factor, or MC growth factor. The interaction between KIT and its ligand leads to dimerization of the receptor and activation of its intrinsic tyrosine kinase activity and drives a variety of downstream signal transduction pathways. The transduction process involves different players such as PI3 kinase, Src family kinases, the Ras-Erk pathway, and JAK/STAT, resulting in cell proliferation, survival, and migration. Aberrant activation of the KIT receptor, caused by gain-of-function mutations of the gene, is a frequent event in SM and results in uncontrolled production and proliferation of MCs. The first identification of somatic gain-of-function mutations in the KIT gene occurred in the HMC-1 human MCL cell line. Two heterozygous point mutations of KIT were revealed: a substitution of aspartic acid with valine at residue 816 (KIT D816V) and a substitution of valine with glycine at residue 560 (KIT V560G). D816V and V560G are the prototypes of two distinct categories of activating mutations, displaying different oncogenic properties and sensitivity to tyrosine kinase inhibitors (TKIs) (Figure 1). The first can indeed be classified as an 'enzymatic pocket' mutation since it falls in the activation loop at the entrance of the enzymatic pocket. The activation loop serves as a sort of molecular switch for kinase activity, and D816V turns it permanently on. Given its strategic position with respect to the enzymatic pocket, this mutation is an obstacle to the binding of some TKIs, like imatinib. The second, in contrast, belongs to the wider category of 'regulatory type' mutations. It is located in the intracellular juxta-membrane domain of the receptor, which has a critical auto-inhibitory function; thus, it results in constitutive kinase activation.

Figure 1. Representation of KIT receptor structure and position of the major mutations. The figure shows the receptor under its monomeric form. The extracellular domain (ECD) (light blue) is characterized by 5 Immunoglobulin (Ig)-like domains that contain a ligand binding site for stem cell factor (SCF) and a dimerization site. The cytoplasmic region contains a transmembrane domain (light green) made by a single helix. The intracellular portion (dark blue) contains an auto-inhibitory juxta-membrane domain (yellow) and a kinase domain (orange) which is split into two parts: an ATP-binding domain and a phosphotransferase domain, linked by a kinase insert. On the left, two distinct categories of KIT activating mutations are reported: the 'regulatory type' mutations (with the V560G being the most frequent), that are located in the juxta-membrane domain; and the 'enzymatic pocket' mutations (best exemplified by the D816 mutations), that fall in the phosphotransferase domain. Though much rarer, the first category of mutations can be addressed by a wider spectrum of inhibitors, including imatinib. The second category of mutations, in contrast, impacts on kinase conformation, thus can be addressed, at present, only by midostaurin (approved) avapritinib and ripretinib (investigational).
‘Regulatory type’ mutations may also affect the binding of substrates or signal transducing or regulatory molecules, or induce ligand-independent dimerization with subsequent autophosphorylation and activation of the kinase. The greatest majority of SM patients, irrespective of the WHO sub-type, display the D816V mutation. More rare variants like D816Y, D816F, D816H, and D816I have occasionally been detected. Less common (<5%) KIT mutations at other codons (mostly belonging to the 'regulatory type' class) have been reported. Rare germline KIT mutations associated with familial mastocytosis have also been reported, including F522C, A533D and K509I. For these forms, the tyrosine kinase inhibitor imatinib offers a valuable therapeutic option. Moreover, several non-D816V mutations have anecdotally been reported in MCL and mast cell sarcomas. Mital et al. reported one case of MCL with a p.A502_Y503dup mutation in exon 9. Other studies conducted in patients with MCL and mast cell sarcomas described KIT mutations at exon 10, exon 11, and exon 13. Finally, children with CM display missense KIT mutations targeting exon 17 at codon 816 but also several alterations in exons 8 and 9 involving the fifth Ig loop of the KIT extracellular domain and leading to constitutive activation of the receptor.

The abnormal kinase activity of KIT has been documented in other human malignancies such as germ cell tumors, melanoma, GIST, and acute myeloid leukemia (AML).

The Role of KIT Mutation Detection in the Diagnostic Workout of SM. The current WHO classification of mastocytosis defines one major and four minor diagnostic criteria for SM. The major SM criterion is the presence of multifocal dense aggregates of MCs in bone marrow (BM) or other visceral organs (at least 15 MCs/cluster). Minor SM criteria include: i) abnormal morphology of MCs (>25%), ii) expression of CD2 and/or CD25 in MCs, iii) persistent serum tryptase concentration >20 ng/mL, and iv) presence of the KIT D816V point mutation in the BM or another extracutaneous organ. If at least one major and one minor or three minor SM criteria are fulfilled, the diagnosis of SM can be established.

The European Competence Network on Mastocytosis (ECNM) suggests an algorithm for patients with suspected (systemic) mastocytosis and provides essential technical guidelines for KIT mutation detection. In The case of suspected mastocytosis in an adult patient without skin lesions and average or slightly increased tryptase level, the presence of KIT D816V mutation may be investigated at first in peripheral blood (PB). If the D816V mutation is detected in PB cells, a BM examination is recommended. In adult patients with suspected mastocytosis and documented skin involvement, a BM investigation is required. In the non-availability of fresh BM aspirate sample, KIT mutational analyses can be performed on cells detached from BM smears or a paraffin-embedded biopsy sample (Figure 2).

In most SM patients, particularly ISM patients, the MC burden, that is, the number of neoplastic MCs infiltrating the BM, is very low. Moreover, mononuclear cells (MNCs) from PB are almost invariably KIT D816V negative when investigated by low sensitivity techniques. This means that sensitivity is crucial to avoid false-negative results and misdiagnosis. Over the past few years, substantial advances have been made to develop more and more sensitive and accurate diagnostic assays. Chronologically, the following techniques have been proposed for KIT D816V mutation testing. They all have advantages as well as disadvantages and differ in terms of lower detection limit, target mutation(s), and requirement of dedicated instrumentation: i) RT-PCR plus restriction fragment length polymorphism (RFLP), ii) nested RT-PCR followed by denaturing high-performance liquid chromatography (D-HPLC) of amplicons, iii) peptide nucleic acid (PNA)-mediated PCR, iv) ASO-qPCR on DNA or cDNA, v) droplet digital PCR (ddPCR) and vi) Next-generation
sequencing (NGS).

**RT-PCR plus RFLP:** it is a simple, cheap, and fast technique that allows identifying the KIT D816V mutation with a sensitivity of 0.05%. No dedicated instrumentation is needed except for a thermal cycler and an electrophoretic system. However, it is not quantitative, and it does not allow the detection of D816 variants and the identification of mutations at other codons.31

**Nested RT-PCR followed by D-HPLC of amplicons:** this assay allows detecting different KIT mutations in the same reaction.32 Nevertheless, it has a relatively low sensitivity (0.5-1%), and it is not quantitative. Moreover, it is time-consuming and needs expensive and not widely available instrumentation (D-HLPC).

**PNA-mediated PCR:** it is the recommended method for FFPE BM trephine biopsies.31 It allows detection of KIT mutations at position 816 or in adjacent codons, but it is not a quantitative assay, and it has an intermediate sensitivity (0.1%).33

**ASO-qPCR:** it is a simple, fast, cheap, reliable, and highly sensitive method (0.01%) that allows to detect and quantify KIT D816V in different tissues and specimens (BM, PB, and organ biopsies).34,35 However, it requires standard curves for the quantitative assessment, thorough validation, and possibly multi-laboratory standardization.

**Droplet Digital PCR:** it is a promising new method for sensitive and accurate quantification of KIT D816V with a sensitivity of 0.01%.36 Moreover, ddPCR has been shown to sensitively and reproducibly detect and quantify KIT D816V in FFPE material.37 In contrast to ASO-qPCR, absolute quantification does not need a standard curve; thus, it is more straightforward. Commercial kits are available.

**Next-generation sequencing (NGS):** it has the lowest sensitivity (1-5%), but it is the best remaining option to study those patients who have no evidence of mutations at codon 816. Commercial myeloid panels are available that include several KIT hotspot exons among their target genes. Such panels may also highlight the presence of mutations in genes other than KIT, providing additional prognostic information (see below).

Being by far the most common, the presence of a KIT D816V needs to be investigated first. However, in the case of D816V negativity, variants like D816Y, D816H, etc., should be ruled out. If no mutation at all can be identified at codon 816, more rare mutations in other KIT exons (like those mentioned in the previous section) should be investigated. A stepwise approach is thus needed. For D816V detection and quantitation, ASO-qPCR or ddPCR are the most frequent option. D816 variants in confirmed D816V-negative patients may be investigated using PNA-mediated PCR. Mutations in other hotspot regions of the KIT gene may then be assessed by Next Generation Sequencing (NGS).

**Prognostic Implications of KIT D816V Allele Burden Quantification and of Multilineage Involvement.** For the assessment of KIT D816V, quantitative methods are desirable for several reasons. The measurement of KIT D816V mutation percentage (the so-called ‘allele burden’) has prognostic significance and can also be employed for monitoring treatment response and disease progression. Recent studies show that the KIT D816V allele burden is indicative of the WHO SM subtype and correlated with the severity of the disease.36,40 Indeed, patients with AdvSM show a significantly higher KIT D816V mutation percentage compared to ISM and CM patients, the latter showing the lowest KIT D816V allele burden. The higher KIT D816V allele burden in AdvSM may be associated with the presence of non-MC-lineage cells harboring the KIT D816V mutation and could explain why it is not always correlated with the number of MC in BM biopsies, and it is only moderately associated with serum tryptase levels. It is now well known that some ISM and all AdvSM patients display a
multilineage disorder whose characteristics are closely related to the risk of disease progression. In fact, the KIT D816V mutation is detected not only in bone marrow MCs but also in myeloid and lymphoid hematopoietic cell lineages, supporting the stem cell origin of this disease starting from a hematopoietic precursor with the ability for multilineage differentiation. The greater or smaller involvement of non-MC-lineage cells harboring the KIT D816V mutation reflects the risk of evolving to a more aggressive subtype of the disease. Therefore, SM patients with multilineage KIT D816V mutation have been shown to have a higher probability of progression compared to patients with MC-restricted KIT D816V.

The assessment of the KIT D816V allele burden also has a remarkable potential in monitoring treatment response. Hoermann et al. observed that in SM patients with stable clinical course, there were not variations in the KIT D816V allele burden, while advSM patients with disease progression showed a marked increase. In line with this, Jawhar et al. used the measurement of KIT D816V allele burden for monitoring midostaurin-treated AdvSM patients. They showed that at month 6 of therapy, a significant reduction ≥25% of the allele burden was the strongest on-treatment predictor for improved survival.

The KIT D816V allele burden was also identified as a prognostic factor regarding overall survival (OS), and to the purpose, a cut-off of ≥ or <2% mutant alleles was used to define two distinct SM groups with different survival times. The group under the cut-off level had a significantly longer life expectancy compared to patients over the 2% cut-off.

These findings are still under validation, but the wider implementation of KIT D816V allele burden assessment in clinical practice holds the potential to improve treatment and monitoring of patients with SM.

**Molecular Alterations Additional to KIT Mutations.**

The somatic KIT D816V mutation is undoubtedly the major driver of SM pathogenesis. However, it is detectable both in patients with ISM, who have a relatively benign prognosis and in patients with AdvSM, who are frequently characterized by rapidly deteriorating clinical courses and poor outcomes. Furthermore, while childhood-onset and adult-onset mastocytosis are both associated with activating KIT mutations, the natural history of the two conditions is quite different. Together with experimental shreds of evidence suggesting that KIT D816V alone is not a fully transforming oncprotein, this emphasized the importance of a better understanding of SM pathogenesis. Prognostically relevant mutations additional to KIT have now been identified in AdvSM. These have been found to affect genes encoding for epigenetic regulators (ASXL1, DNMT3A, EZH2, TET2), transcription factors (RUNXI), signaling molecules (CBL, JAK2, KRAS, NRAS), or splicing factors (SRSF2, SF3B1, U2AF1). These mutations are not specific for SM but are frequently detected in myeloid neoplasm, including myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), chronic myelomonocytic leukemia (CMMI), and acute myeloid leukemia (AML) where they are often associated with poor prognosis and shorter survival. TET2 mutations are detected in 20-40% of AdvSM patients. Evidence in mice suggests that the cooperation between KIT D816V and the loss of function of TET2 induces a transformation to a more aggressive disease phenotype. Moreover, when TET2 mutations are associated with DNMT3A mutations, the prognosis of SM patients is severely impaired compared to those with wild-type genes. Analogously to TET2, the presence of other mutations additional to KIT may confer an adverse prognosis compared with patients without such abnormalities. Jawhar et al. were the first to observe that in SM-AHN, the presence and number of mutated genes within the SRSF2/ASXL1/RUNX1 (S/A/R) panel was associated with poor outcome and adverse clinical characteristics. In particular, mutations in TET2 and ASXL1 were the most predictive adverse indicators concerning OS. As expected, these mutations were observed at a higher frequency in ASM-AHN and MCL-AHN and at a lower frequency in ISM-AHN. Muñoz-González et al. suggested that, in addition to S/A/R gene panel, somatic EZH2 gene mutations can be detected in SM patients who show a higher risk of disease progression.

Moreover, the overall response rate (ORR) and OS were significantly higher in patients S/A/Rpos than in patients S/A/Rneg. The Mayo Clinic group evaluated the impact of ASXL1 and/or CBL mutations and the occurrence of ≥3 non-KIT mutations on the clinical outcome of AdvSM patients and showed that they were independently associated with inferior OS. Moreover, based on clinical and molecular parameters (including ASXL1 mutations), Pardanani et al. proposed a "mutation-augmented" prognostic scoring system to stratify advSM patients into 3 subgroups: low-, intermediate- and high-risk with significantly different OS. Alternative prognostic scoring systems that include information about S/A/R profiling and other molecular markers have been proposed, and others are still under investigation.

**KIT as Therapeutic Target.** The clinical spectrum of this disease is highly heterogeneous. The treatment should be individualized and related to symptoms and diagnosis of each patient. Therapy of CM is mainly directed towards skin lesions. Anti-mediator drug therapy for MC activation symptoms represents the mainstay of treatment for symptomatic CM, ISM and SSM however, it should be considered in all SM patients. The goal is to regulate mediator secretion,
Several TKIs, such as imatinib, nilotinib, and masitinib, have shown activity against wild-type KIT. They belong to type II TKI inhibitors, so they recognize only the inactive conformation of the receptor and stabilize it. The presence of mutations in the activation loop (like KIT D816V) that result in a constitutively active conformation of the receptor renders it inaccessible to type II inhibitors. Imatinib (IM) is currently approved by the FDA for the treatment of ASM with WT KIT or with unknown KIT mutational status. It demonstrated activity against certain trans-membrane (F522C) and juxta-membrane (V560G) KIT mutants. IM efficacy has also been reported in a patient with familiar SM with KIT K509I mutations in the germline. However, since the major of SM patients harbor the KIT D816V mutation, it has a limited role in the treatment of this disease. Masitinib was evaluated in phase II multicenter study of SM patients with or without KIT D816V mutation. However, it showed modest clinical benefit, observed only in patients with WT KIT.

Masitinib showed a great in vitro activity in ISM and SSM patients with WT KIT or with KIT mutations outside the phospho-transferase domain, but it has yet to be tested in AdvSM. Type I TKIs (able to bind both the active and the inactive form of kinases) tested in SM include dasatinib, midostaurin, and avapritinib. Dasatinib is a multikinase inhibitor that showed in vitro activity against both WT KIT and KIT activation loop mutants (KIT D816V/Y/F). It was also shown to re-localize KIT D816V from the cytoplasm to the cell surface. Interestingly, the extent of this re-localization correlates with SM severity (AdvSM > ISM).

Midostaurin is another multikinase inhibitor; currently, the only TKI approved for the treatment of AdvSM. The encouraging results related to the use of midostaurin in a patient with MCL led to a multicenter phase II study (CPK412D2213) of midostaurin in 26 AdvSM patients. Results consisted in an unprecedented overall response rate (ORR) of 69% regardless of KIT mutational status, with 38% of Major Responses (MR)(complete resolution of at least one clinical(C)-finding such as cytopenias, osteolyosis with or without pathologic fractures, hepatosplenomegaly and/or with impaired liver function and/or ascites, and malabsorption). Starting from these data, a global phase II trial (CPK412D2201) was initiated to evaluate the efficacy and safety of midostaurin in 89 AdvSM patients. The ORR was 60% and was independent of KIT mutation status and the number of previous therapies. Almost half of the patients (45%) had an MR, 15% had a partial response. After the closure of this study, a compassionate use program of midostaurin was approved in France. ORR was 71%, with a median response duration of 17 months. The most frequent adverse effects of midostaurin are low grade (nausea, vomiting, diarrhea), but also new or worsening grade 3 or 4 (neutropenia, anemia, and thrombocytopenia) adverse events can be observed.

Finally, avapritinib is a type I kinase inhibitor that selectively inhibits the activation-loop mutants of KIT (exon 11/17, including KIT D816V). It is approved in the USA for PDGFRa exon 18 mutant gastrointestinal stromal tumors (GIST), and it is also in clinical development for SM treatment. The phase I study (Explorer; NCT02561988) in adult patients with AdvSM has demonstrated potent antineoplastic activity of avapritinib across all advSM subtypes with complete (disappearance of all target lesions) and durable responses. The ORR was 77%; 74% of patients maintained the response for at least 12 months. Avapritinib was also showed to improve overall symptoms of SM. Avapritinib is currently being evaluated in an ongoing, double-blind, placebo-controlled, phase II study (Pioneer), where SM patients with moderate or severe symptoms, refractory to ≥2 best supportive care drugs, are enrolled. Most adverse reactions of this drug are of grade 1 or 2.

Another agent under investigation is ripretinib (DCC-2618). It is a type II kinase inhibitor designed to inhibit the full spectrum of mutant KIT and PDGFRa. In addition, it shows strong activity against activation loop mutants, previously thought to be only achievable with type I inhibitors. Its efficacy and safety are being tested in a Phase I open-label dose-escalation study (NCT02571036) to treat AdvSM, GIST, and advanced cancer.

**Other Non-KIT Targets and Novel Agents.** Several studies have shed light on novel altered pathways involved in the pathogenesis of SM. Under normal conditions, SCF binds KIT receptor leading to its dimerization and activation. This binding activates several downstream signaling molecules involved in the proliferation and survival of MCs, such as the phosphatidylinositol triphosphate kinase (PI3K), the Janus kinase (JAK)/signal transducers and activators of transcription (STAT), and the rat sarcoma (RAS)/extracellular signal-regulated kinases (ERK). The presence of the KIT D816V mutation contributes to divert these pathways leading to a malignant transformation of MCs.

Baumgartner et al. showed that the SM-related oncoprotein KIT D816V promotes STAT5 activation...
and phosphorylation and that pSTAT5 contributes to the growth of neoplastic MCs.\textsuperscript{87} Moreover, STAT5 was found to localize to the cytoplasm and to form a signaling complex with PI3K,\textsuperscript{88} whose activation has been described to be constitutively associated with D816V KIT mutant.\textsuperscript{89} Once activated, PI3K activates its downstream effector AKT promoting MCs growth and survival. This evidence suggests that the STAT5-PI3K-AKT pathway plays an important role in the pathogenesis of SM. Indeed, the knock-down of either STAT5 or AKT activity resulted in growth inhibition of KIT D816V+ neoplastic MCs.\textsuperscript{88} Therefore, drugs targeting the STAT5- PI3K-AKT axis should be considered a potentially novel therapeutic approach in SM patients. Another interesting strategy may be targeting the JAK/STAT signaling pathway. Starting from the evidence that there is often an increased expression of JAK/STAT pathway components in SM, Lasho et al. showed KIT D816V -mediated cell growth decrease in MC cell lines treated with the JAK2 inhibitor TG101348.\textsuperscript{90}

One of the major pathways downstream PI3K is represented by rapamycin (mTOR). It is a serine/threonine kinase found in two protein complexes called mTOR complex 1 (mTORC1) and complex 2 (mTORC2). PI3K is able to regulate the mTORC1 pathway by the activation of AKT. Once activated, AKT directly phosphorylates the negative regulator of mTOR, leading to mTOR activation and phosphorylation of two effector molecules: p70 ribosomal S6 kinase (p70S6K) and eukaryotic initiation factor 4E-binding protein1 (4E-BP1).\textsuperscript{91} The increased activation of the mTORC1 pathway, reported in neoplastic MCs lines and immature MCs,\textsuperscript{92} seems to contribute to MCs dysregulated proliferation and survival. Therefore, the inhibition of mTORC1 by rapamycin should be considered to contrast this event. Indeed, it has been shown to block mTORC1-dependent p70S6K phosphorylation.\textsuperscript{93} Moreover, the dual PI3K/mTOR blocker NVP-BEZ235 showed profound inhibitory effects on the growth of primary and neoplastic MCs \textit{in vitro}.\textsuperscript{93}

In addition to KIT downstream effectors, other non-KIT targets have been described as therapeutically interesting. For example, MCL-1, a BCL-2 family member with antiapoptotic properties, was expressed constitutively both in neoplastic MCs of all SM variants and MC leukemia cell lines HMC-1.1 (D816V negative) and HMC-1.2 (D816V positive); furthermore, MCL-1 knock-down mediated by antisense oligonucleotides or specific siRNA resulted in increased apoptosis and a decreased survival of neoplastic MCs, showing synergistic effects in combination with midostaurin and other TKIs including nilotinib and imatinib.\textsuperscript{94} These data indicate that MCL-1 may be a novel, potential target in neoplastic MCs.

KIT D816V was also found to downregulate BIM expression.\textsuperscript{95} BIM is a proapoptotic member of the BCL-2 family that acts as a tumor suppressor in various myeloid neoplasms.\textsuperscript{96-98} The KIT-targeting drug midostaurin was able to induce BIM re-expression in neoplastic HMC-1.1 and HMC-1.2 cells and to promote growth inhibition in both subclones.\textsuperscript{95} Moreover, in the HMC-1 cell line, the use of the proteasome inhibitor bortezomib was associated with a substantial increase in BIM expression and induction of apoptosis. Indeed, several studies have shown that phosphorylated BIM degradation in neoplastic myeloid cells is usually mediated by the proteasome.\textsuperscript{95,99} In addition to midostaurin and bortezomib, Aichberger et al. showed that the pan Bcl-2 blocker obatoclax contributed to inducing growth arrest and promoting apoptosis in HMC-1 cells and had synergic effects with midostaurin.\textsuperscript{95} In summary, BIM acts as a regulator of the growth and survival of neoplastic human MCs. Therefore, promoting BIM re-expression or targeting antiapoptotic members of the Bcl-2 family, combined with a KIT inhibitor, may be a novel, interesting approach in AdvSM patients.

Finally, the loss of function of the SETD2 tumor suppressor gene has recently been reported in AdvSM.\textsuperscript{100} It was already observed in various solid tumors and hematologic malignancies of both myeloid and lymphoid origin.\textsuperscript{101} The SETD2 tumor suppressor gene encodes the only methyltransferase able to tri-methylate histone H3 on lysine 36 (H3K36Me3).\textsuperscript{102} H3K36Me3 by SETD2 is involved in transcriptional fidelity. Moreover, SETD2 plays pivotal roles in RNA alternative splicing regulation, DNA damage repair, and cytoskeleton protein methylation.\textsuperscript{101,103} SETD2 loss of function may be due to biallelic missense or truncating mutations, as seen in acute leukemias, or associated with monoallelic deletions at chromosome 3p and mutations of the remaining allele, as reported in clear cell renal cell carcinoma (ccRCC). However, other mechanisms acting at the transcript or protein level can be observed. In SM, a new post-translational mechanism of SETD2 loss of function has been described: both subclones of the HMC-1 cell line and up to 80% of patients with AdvSM displayed H3K36Me3 deficiency as a result of non-genomic loss of function of SETD2, in the absence of mutations or structural aberrations.\textsuperscript{100} The extent of H3K36Me3/SETD2 downmodulation was correlated with disease aggressiveness (AdvSM-ISM). Proteasome inhibition restored H3K36Me3 and SETD2 protein expression, suggesting that a functional protein is produced but rapidly degraded. Moreover, the treatment with the proteasome inhibitor bortezomib resulted in induction of apoptosis and reduced colony growth both in the HMC-1 cell line and in primary neoplastic MCs from patients with AdvSM. SETD2 loss of function in acute leukemias is often associated with chromosomal...
Moreover, quantitation of status is critical for appropriate diagnostic and therapy. The recent approval of the pan-inhibitor midostaurin (effective against both wild-type and mutant KIT) for the treatment of AdvSM patients has represented a breakthrough and has paved the way for targeted therapy of SM. Additional KIT inhibitors, like avapritinib and ripretinib, are currently being evaluated in clinical trials. As more and more options may become available, comprehensive molecular profiling can assist in individualizing therapy, including treatment intensification of ISM and SSM cases at higher risk of progression. Other novel drug targets (STAT5-PI3K-AKT pathway, mTORC1, MCL-1, BIM, SETD2) have been validated at the preclinical level, but more studies would need to be undertaken before the respective inhibitors can advance to clinical use. Patients with AdvSM failing or not tolerating approved therapies and unfit for transplant might indeed benefit from additional therapeutic options chosen on the basis of their molecular characterization. In this specific, very small setting, repurposing of compounds already tested and approved for other conditions could be more straightforward.

Thus, biological and clinical research move forward in close synergy in SM to offer these rare and long-neglected patients the best quality of life and outcome expectations.

Conclusions and Future Perspectives. Over the past decade, we have witnessed major advances in the molecular characterization of SM. This has provided important information for a better understanding of the pathogenesis of the disease but has also practically impacted the way we diagnose and manage it.

Sensitive and accurate assessment of KIT mutation status is critical for appropriate diagnostic and therapy. Moreover, quantitation of KIT D816V allele burden has prognostic significance and can be employed for monitoring treatment response and disease progression. Cooperating mutations in genes other than KIT contribute to the greater aggressiveness of the disease and may provide additional prognostic information. Over the past few years, substantial advances have been made in developing more sensitive and accurate diagnostic assays that have shown the capability to detect the KIT D816V mutation percentage at very low levels (down to 0.001%), and non-invasively in the PB (ASO-qPCR, ddPCR). Both these features are important, considering that SM is generally underdiagnosed.

Moreover, a role for targeted NGS in identifying KIT non-D816V mutants or mutations in other key myeloid genes has been recently established. The same myeloid aberrations and activated gene expression in the mTOR and Jak/Stat signaling pathways, contributing directly to leukemogenesis in acute leukemias and SM. All these data suggest that reversion SETD2 loss of function, in combination with KIT-targeting drugs, could be a promising therapeutic strategy to improve the prognosis of AdvSM patients who do not respond to or relapse on midostaurin. Further investigations into the mechanisms leading to SETD2 altered turnover in SM and the cooperative effects of KIT constitutive activation and SETD2 loss of function in AdvSM are warranted.

References:

1. Homy HP, Sotlar K, Valent P. Mastocytosis: state of the art. Pathobiology. 2007;74(2):121-32. https://doi.org/10.1159/000101711
2. Wiescher F, Rabenhorst A, Schick T, Preussner LM, Förster A, Valent P, Homy HP, Sotlar K, Hartmann K. Large maculopapular cutaneous lesions are associated with favorable outcome in childhood-onset mastocytosis. J Allergy Clin Immunol. 2015;136(6):1581-1590. https://doi.org/10.1016/j.jaci.2015.05.034
3. Hartmann K, Metcalfe DD. Pediatric mastocytosis. Hematol Oncol Clin North Am. 2000;14(3):625-40. https://doi.org/10.1016/S0889-8588(05)70299-9
4. Lim KH, Tefferi A, Lasho TL, Finke C, Patnaik M, Butterfield JH, McClure RF, Li CY, Pardanani A. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009;113(23):5727-36. https://doi.org/10.1182/blood-2009-02-205237
5. Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. 2017;129(11):1420-1427. https://doi.org/10.1182/blood-2016-09-731893
6. Perri L, Bonadonna P, Elena C, Papayannidis F, Grifoni FJ, Grigioni FL, Rondoni M, Girlanda S, Mauro M, Magliacane D, Erm G, Iorno ML, Almerigogna F, Scard F, Salerno R, Fanelli T, Gesullo F, Corbizi Fattori G, Bonfaccio M, Perbellini O, Artuso A, Soverini S, De Benedittis C, Muratori S, Pravettoni V, Cova V, Cottellini G, Ciceri F, Cortezelezi A, Martinelli G, Triggiani M, Merante S, Vanneluci AM, Zanotti R. Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients. Am J Hematol. 2016;91(7):692-9. https://doi.org/10.1002/ajh.24382
7. Trizuljak J, Sperr WR, Nekvindová L, Elberink HO, Gleixner KV, Gorska A, Lange M, Hartmann K, Illerhaus A, Bonfaccio M, Perkins C, Elena C, Malcovati L, Fortina AB, Shoumariyeh Y, Jawhar M, Zanotti R, Bonadonna P, Caroppo F, Zink A, Triggiani M, Parente R, van Bubnoff N, Yavuz AS, Hägglund H, Mattsson M, Pasne J, Jäkel N, Kilbertus A, Hermine O, Arock M, Fuchs D, Sabato V, Brokvog K, Breterkerieber A, Niedoszytko M, van Amoor B, Reiter A, Gotlib J, Kluin-Nelemans HC, Mayer J, Doubek M, Valentin P. Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification. Allergy. 2020;75(8):1927-1938. https://doi.org/10.1111/all.14248
8. Pardanani A, Tefferi A. Systemic mastocytosis in adults: a review on prognosis and therapy. Mayo Clin Proc. 2015;90(7):917-927. https://doi.org/10.1016/j.mayocp.2015.04.004
9. Tefferi A, Shah S, Reichard KK, Hanson CA, Pardanani A. Smoldering mastocytosis: Survival comparisons with indolent and aggressive mastocytosis. Am J Hematol. 2019;94(1):E1-E2. https://doi.org/10.1002/ajh.25302
25. Gari M, Goodeve A, Wilson G, Winship P, Langabeer S, Linch D, Vandenbergh E, Peake I, Reilly J. c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. Br J Haematol. 1999;105(4):894-900. https://doi.org/10.1046/j.1365-2141.1999.01449.x

26. Goemens BF, Zwaan CM, Miller M, Zimmermann M, Harlow A, Meshinchi S, Loonen AH, Hähnel K, Reinhardt D, Creutzig U, Kaspers GJ, Heinrich MC. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukaemia. Leukemia. 2005;19(9):1536-42. https://doi.org/10.1038/sj.leu.2403870

27. Hartmann K, Mannel E, Ma Y, Merkelbach-Bruse S, Preussner LM, Hermann K, Nebenbaur H, Schwartz LB, Castells M, Maurer M, Horny HP, Akin C, Metcalfe DD, Arock M. European Competence Network on Mastocytosis. Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis. Allergy. 2014;69(10):1267-74. https://doi.org/10.1111/all.12436

28. Akin C, Arock M, Sotlar K, Cirmaci G, Hoermann G, Escribano L, Krishen TK, Khinn-Nelms-HC, Hornie, O, Dubreuil P, Sperr WR, Hartmann K, Gotlib J, Cross NC, Haferlach T, Garcia-Montero A, Orfao A, Schwarz, J, Triggianni M, Horny HP, Metcalfe DD, Reiter A, Valerent P. KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. Leukemia. 2015;29(6):1223-32. https://doi.org/10.1038/leu.2015.24

29. Sotlar K, c-kit mutational analysis in paraffin material. Methods Mol Biol. 2013;999:59-78. https://doi.org/10.1007/978-1-62703-357-2_4

30. Fritsch-Polanez R, Jordan JH, Feix A, Sperr WR, Sander-Plassmann G, Valentin P, Födinger M. Mutation analysis of KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol. 2011;153(2):357-64. https://doi.org/10.1111/j.1365-2141.2001.07283.x

31. Erben P, Schwaab J, Metzgerth G, Horny HP, Jawhar M, Sotlar K, Fabarius A, Teichmann M, Schneider S, Ernst T, Müller MC, Giel M, Marx A, Hartmann K, Hochhaus A, Hofmann WK, Cross NC, Reiter A. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. Ann Hematol. 2014;93(1):81-8. https://doi.org/10.1007/s00277-013-1964-1

32. Sotlar K, Escribano L, Landt O, Möhrle S, Herrero S, Torrelo A, Lass U, Horny HP, Bülltmann B. One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol. 2005;163(2):717-26. https://doi.org/10.1016/S0002-9440(10)63870-9

33. Schumacher JA, Enlentio-Donson KS, Lim MS. Detection of the KIT D816V mutation in systemic mastocytosis by allele-specific PCR. J Clin Pathol. 2008;61(1):109-14. https://doi.org/10.1136/jcp.2007.047928

34. Kristensen T, Broesby-Olsen S, Vestergaard B, Sotlar K, Müller MB, Mastocytosis Centre Odense University Hospital (MastOUH). Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis. Eur J Haematol. 2012;89(1):42-6. https://doi.org/10.1111/j.1600-0609.2012.01789.x

35. Greiner G, Burbisch M, Ratzinger F, Witzeneder N, Simonitst-Klupp I, Mitterbauer-Hohendanner G, Mayerhofer M, Müller L, Sperr WR, Valentin P, Hoermann G. Digital PCR: A Sensitive and Precise Method for Mutation Analysis of KIT in Systemic Mastocytosis. Clin Chem. 2018;64(3):547-55. https://doi.org/10.1373/clinchem.2017.277897

36. Greiner G, Burbisch M, Ratzinger F, Witzeneder N, Class VS, Eisenwert G, Simonitz-Klupp I, Esterhaier H, Mayerhofer M, Mullauer L, Sperr WR, Valentin P, Hoermann G. Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis. Haematologica. 2020;105(2):366-374. https://doi.org/10.3324/haematol.2019.217950
39. Brosky-Olsen S, Oropesa AR, Bindslev-Jensen C, Vestergaard H, Møller MB, Siebenhaar F, Kristensen T, Mortz CG. Mastocytosis Centre Odense University Hospital (MastOUH); Odense Research Centre for Anaphylaxis. Recognizing mastocytosis in patients with anaphylaxis: value of KIT D816V mutation analysis of peripheral blood. J Allergy Clin Immunol. 2015;135(2):262-6.
https://doi.org/10.1016/j.jaci.2014.06.031

40. Hoermann G, Gleixner KV, Dinu GE, Kundi M, Greiner G, Wimazal F, Hadzijusufovic E, Mitterbauer G, Mannhalter C, Valent P, Sperr WR. The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease. Allergy. 2014;69(6):810-3.
https://doi.org/10.1111/all.12409

41. Escribano L, Alvarez-Twose I, Sánchez-Muñoz L, Garcia-Montero A, Núñez R, Almeida J, Araujo-Cedeno M, Teodosio C, Garcia-Cosio M, Bello C. Orrico: Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol. 2009;124(3):514-21.
https://doi.org/10.1067/j.jaci.2009.05.003

42. Akin C, Kirshenbaum AS, Semere T, Worobec AS, Scott LM, Metcalfe DD. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. Exp Hematol. 2000;28(2):140-7.
https://doi.org/10.1054/exhe.2000.0145.9

43. Yavuz AS, Lipsky PE, Yavuz S, Metcalfe DD, Akin C. Evidence for the involvement of a hemopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. Blood. 2002 Jul 15;100(2):661-5.
https://doi.org/10.1182/blood.2002-01-2020

44. Kocabaş CN, Yavuz AS, Lipsky PE, Metcalfe DD, Akin C. Analysis of the lineage-related relation between mast cells and basophils using the c-kit D816V mutation as a biologic signature. J Allergy Clin Immunol. 2005;115(6):1155-61.
https://doi.org/10.1016/j.jaci.2005.02.030

45. Jawhar M, Schwab J, Naumann N, Horny HP, Solfar L, Haferlach T, Metzgeroth G, Fabarius A, Valent P, Hofmann WK, Cross NPC, Meggendorfer M, Reiter A. Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers. Blood. 2017;130(2):137-145.
https://doi.org/10.1182/blood-2017-01-764232

46. Schwab J, Schnittert S, Solfar L, Walz C, Fabarius A, Pfirrmann M, Kohlmann A, Grossmann V, Meggendorfer M, Horny HP, Valent P, Jawhar M, Teichmann M, Metzgeroth G, Erben P, Ernst T, Hochhaus A, Haferlach T, Hofmann WK, Cross NC, Reiter A. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood. 2013;122(14):2460-6.
https://doi.org/10.1182/blood-2013-04-496448

47. Tefferi A, Levine RL, Lim KH, Abdel-Wahab O, Lasho TL, Pinke C, Zbierski DL, Abdelrahman RA, Wassie EA, Gangat N, Haferlach T, Ketterling RP, Tefferi A. ASXL1 and CBL mutations are independently predictive of inferior survival in advanced systemic mastocytosis. Br J Haematol. 2016;175(3):534-536.
https://doi.org/10.1111/bjh.13865

48. Pardanani AD, Lasjo TL, Pinke C, Zbierski DL, Abdelrahman RA, Wassie EA, Gangat N, Haferlach T, Ketterling RP, Tefferi A. Next-generation sequencing in systemic mastocytosis: Derivation of a mutation-augmented clinical prognostic model for survival. Am J Hematol. 2016;91(9):888-93.
https://doi.org/10.1002/jjco.24246

49. Jawhar M, Schwab J, Alvarez-Twose I, Shoumariyeh K, Naumann N, Lähderanta E, Perkins C, Muñoz-González JI, Meggendorfer M, Kennedy V, Metzgeroth G, Fabarius A, Pfeifer D, Solfar L, Horny HP, von Bubnoff N, Haferlach T, Cross NPC, Hofmann WK, Sperr WR, Garcia-Montero AC, Valent P, Gotlib J, Orfao A, Reiter A. MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis. J Clin Oncol. 2019;37(31):2846-2856.
https://doi.org/10.1200/JCO.19.00640

50. Muñoz-González JI, Alvarez-Twose I, Araujo-Cedeno M, Henrques A, Viñas E, Prieto C, Sánchez-Muñoz L, Cadals C, Mayoada A, Matito A, Dasilva-Freire N, Orfao A, García-Montero AC. Frequency and prognostic impact of KIT and other genetic variants in indolent systemic mastocytosis. Blood. 2020;144(1):e1-e14.
https://doi.org/10.1182/bloodadvances.2018026245

51. Pardanani AD, Shah S, Mannelli F, Elaia YC, Guglielmelli P, Lasho TL, Patnaik MM, Gangat N, Ketterling RP, Reichard KK, Hansen CA, Vannucchi AM, Tefferi A. Mayo alliance progenic system for mastocytosis clinical and hybrid-clinical-molecular models. Blood Adv. 2018;2(21):2964-2972.
https://doi.org/10.1182/bloodadvances.2018886507

52. Jawhar M, Schwab J, Alvarez-Twose I, Shoumariyeh K, Naumann N, Lähderanta E, Perkins C, Muñoz-González JI, Meggendorfer M, Kennedy V, Metzgeroth G, Fabarius A, Pfeifer D, Solfar L, Horny HP, von Bubnoff N, Haferlach T, Cross NPC, Hofmann WK, Sperr WR, Garcia-Montero AC, Valent P, Gotlib J, Orfao A, Reiter A. MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis. J Clin Oncol. 2019;37(31):2846-2856.
https://doi.org/10.1200/JCO.19.00640

53. Muñoz-González JI, Alvarez-Twose I, Araujo-Cedeno M, Henrques A, Viñas E, Prieto C, Sánchez-Muñoz L, Cadals C, Mayoada A, Matito A, Dasilva-Freire N, Orfao A, García-Montero AC. Frequency and prognostic impact of KIT and other genetic variants in indolent systemic mastocytosis. Blood. 2020;144(1):e1-e14.
https://doi.org/10.1182/bloodadvances.2018026245

54. Speer WR, Kundi M, Alvarez-Twose I, van Amooroo B, Oude Elberink JNG, Gorska A, Niedoszytko M, Gleixner KV, Hadzijusufovic E, Zanotti R, Bonadonna P, Bonificcio M, Perkins C, Illerhaus A, Elena C, Merante S, Shoumariyeh K, von Bubnoff N, Parente R, Jawhar M, Belloni Fortina A, Caroppo F, Brockow K, Zink A, Fuchs D, Kilbertus AJ, Yavuz AS, Doubeik M, Häglund H, Panse J, Sabato V, Brettekleieker A, Niederwieser D, Breyer M, Klammt R, Hertwig M, Mitterbauer G, von Bubnoff N, Lehmann H, Frenzel R, Ketterling RP, Reichard KK, Hansen CA, Vannucchi AM, Tefferi A. Mayo alliance prognostic system for mastocytosis clinical and hybrid-clinical-molecular models. Blood Adv. 2018;2(21):2964-2972.
https://doi.org/10.1182/bloodadvances.2018886507

55. Scheber RM, Boran AT, Balcioglu A. Systemic mastocytosis: diagnosis and treat system mastocytosis in adults. Br J Haematol. 2018;180(1):11-23.
https://doi.org/10.1111/bjh.14967

56. Pardanani AD. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management. Am J Hematol. 2019;94(3):363-377.
https://doi.org/10.1002/ajh.25371

57. Buttimer JH. Response to interferon in systemic mastocytosis. Br J Dermatol. 1998;138(4):389-95.
https://doi.org/10.1046/j.1365-2133.1998.01211.x

For the full reference list, please see the original article.
65. Butterfield JH, Tefferi A, Kozuh GF. Successful treatment of systemic mastocytosis with high-dose interferon-alpha: long-term follow-up of a case. Leuk Res. 2005;29(2):131-4. https://doi.org/10.1016/j.leukres.2004.05.003

66. Hanssrich AW, Simonitsch-Klappe I, Uffmann M, Koller E, Sperr WR, Lechner K, Valent P. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leuk Res. 2004;28(3):249-57. https://doi.org/10.1016/j.leukres.2003.04.059

67. Pardanani A, Hoffbrand AV, Butterfield JH, Tefferi A. Treatment of systemic mast cell disease with 2-chlorodioxidemuson. Leuk Res. 2004;28(2):127-31. https://doi.org/10.1016/j.leukres.2003.04.059

68. Böhm A, Sonneck K, Gleixner KV, Schuch K, Pickl WF, Blatt K, Peter B, Herrmann H, Schernthanher GH, Pehamberger H, Rabitsch W, Sperr WR, Valent P. In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V. Exp Hematol. 2010;38(9):744-55. https://doi.org/10.1016/j.exphem.2010.05.006

69. Klui-Nelemens HC, Oldhoff JM, Van Doornmaal JJ, Van 't Wout JW, Verhoef G, Gerrits WB, van Dobbenburgh OA, Pasmans SG, Fijnheer R. Cladribine therapy for systemic mastocytosis. Blood. 2003;102(13):4270-6. https://doi.org/10.1182/blood-2003-11-3816

70. McMahon G, Longley BJ. The c-kit mutation causing human mastocytosis is a dominant-negative inhibitor of wild-type c-kit. Blood. 2002;99(5):1741-4. https://doi.org/10.1182/blood.V99.5.1741

71. Hochhaus A, Baccarani M, Giles LJ, le Coutre PD, Müller MC, Reiter A, Kluin-Nelemans HC, Cohen PS, Arber DA, Heinrich MC, Neckers L, Galli SJ, Gilliland DG, Lortholary O, Arock M, Hermine O, Dubreuil P, Wadler S, Mann S, Druker BJ, Heinrich MC, Reiter A. Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. N Engl J Med. 2016;374(26):2530-41. https://doi.org/10.1056/NEJMoa1513098

72. Chassang MO, Damia G, Canioni D, Brouzes C, Lhermite L, Hanssens K, Frenzel L, Cherquiouz Q, Durieu I, Durupt S, Gyan E, Beyne-Rauzy O, Launay D, Faure C, Hamidou M, Besnard S, Diouf M, Schiffmann A, Niault M, Jantel PY, Ranta D, Gressin R, Chantepe S, Barete S, Dubreuil P, Bourget P, Lortholary O, Hermine O; CEREMAST Study Group. Midostaurin in Advanced Systemic Mastocytosis. N Engl J Med. 2016;374(26):2605-7. https://doi.org/10.1056/NEJMoa1515403

73. Radia D, Deininger MW, Gotlib J, Bose P, Drummond MW, Hexner E, Robinson W, Querry A, Winton E, George TI, Horny HP, Oren R, Shi H, Schmidt-Kittler O, Mar B, DeAngelo D. Avapritinib, a potent and selective inhibitor of Kit D816V, induces complete and durable responses in patients (pts) with advanced systemic mastocytosis (AdSM) (abstract no. S830 and oral presentation). HemaSphere. 2019. https://doi.org/10.1071/HS000561.891213.82

74. Maier M, Elberink HO, Gotlib J, Sabaté M, Hartmann K, Brosy- Olsen S, Castells M, Deininger M, Heaney M, Tenenbaum M, Siebenhaar F, Radia D, Triggiani M, Daele P, DeAngelo D, Schmidt-Kittler O, Lin H, Mauerer A, Mar B, Mauer M. Results from PIONEER: a randomized, double-blind, placebo-controlled, phase 2 study of avapritinib in patients with indolent systemic mastocytosis (ISM). Oncol Res Treat. 2020;43:77-87.

75. Smith BD, Kaufman MD, Lu WP, Gupta A, Leary CB, Wise SC, Rutkowski TJ, Ahn YM, Al-Ani G, Bulfer SL, Caldwell TM, Chun L, Ensinger CL, Hood MM, McKinley A, Patt WC, Ruiz-Soto R, Su Y, Telikapalli H, Town A, Turner BA, Vogeti L, Vogeti S, Yates J, Janku F, Abdul Razak AR, Jensen O, Liphardt DL, Loewith R, Horwich AL, Oparil DL, DCC-2618 Study Group. Switch Kinase Inhibition of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants. Cancer Cell. 2019;35(5):738-751.e9. https://doi.org/10.1016/j.ccell.2019.04.006

76. Baumgartner C, Cerry-Reitterer S, Sonnek M, Mayerhofer M, Gleixner KV, Fritz R, Kerenyi M, Boudot C, Guilloux F, Komfeld WJ, Sillaber C, Moriggl R, Valentin P. Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein Kit D816V. Am J Pathol. 2009;175(6):2416-29. https://doi.org/10.2353/ajpath.2009.080953

77. Harir N, Boudot C, Friedbichler K, Sonnek K, Kondo R, Martin-Lannereau S, Kenner L, Kerenyi M, Yahioue S, Guilloux-Gruart V, Gondry J, Benit L, Duansaung F, Lassoed K, Valentin P, Moriggl R, Guilloux F. Oncogenic Kit controls neoplastic mast cell growth through a selective inhibition of Stat5. Oncol Res. 2008;14(12):3906-15. https://doi.org/10.1056/NEJMc1513098

78. Sundström M, Vilagofos H, Karlberg P, Butterfield JH, Nilsson K, Metcalfe DF, Nilsson G. Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c-kit proto-oncogene. Int Immunol. 2003;15(1):89-97. https://doi.org/10.1093/immunol/12.8.857

79. Lasho T, Tefferi A, Pardanani A. Inhibition of JAK-STAT signaling by TG101348: a novel mechanism for inhibition of KitD816V-dependent growth in mast cell leukemia cells. Leukemia. 2010;24(7):1378-80.
91. Kim MS, Kuehn HS, Metcalfe DD, Gilfillan AM. Activation and function of the mTORC1 pathway in mast cells. J Immunol. 2008;180(7):4586-95. https://doi.org/10.4049/jimmunol.180.7.4586

92. Smrz D, Kim MS, Zhang S, Mock BA, Smrzová S, DaBois W, Simakova O, Maric I, Wilson TM, Metcalfe DD, Gilfillan AM. mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells. Blood. 2011;118(26):6803-13. https://doi.org/10.1182/blood-2011-06-359984

93. Blatt K, Herrmann H, Mirzka I, Hadzijusufiovic E, Peter B, Strommer S, Hoermann G, Mayerhofer M, Hoetzeneker K, Klepetko W, Ghanian V, Marth K, Füreder T, Wacheck V, Volenta R, Valent P. The PI3-kinase/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophils. PLoS One. 2012;7(1):e29925. https://doi.org/10.1371/journal.pone.0029925

94. Aichberger KJ, Mayerhofer M, Gleixner KV, Krauth MT, Gruze A, Pickl WF, Wacheck V, Selzer E, Müllauer L, Agis H, Sillaber C, Valent P. Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412. Blood. 2007;109(7):3031-41. https://doi.org/10.1182/blood-2006-07-032714

95. Shintyo T, Kuribara R, Inukai T, Hosoi H, Kinoshita T, Miyajima A, Houghton PJ, Look AT, Ozawa K, Inaba T. Downregulation of Bim, a proapoptotic relative of Bcl-2, as a pivotal step in cytokine-initiated survival signaling in murine hematopoietic progenitors. Mol Cell Biol. 2001;21(3):854-64. https://doi.org/10.1128/MCB.21.3.854-864.2001

96. Luciano F, Jacquell A, Colosetti P, Herrant M, Cagnol S, Pages G, Auburger P. Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene. 2003;22(43):6785-93. https://doi.org/10.1038/sj.onc.1206792

97. Aichberger KJ, Mayerhofer M, Krauth MT, Vales A, Kondo R, Derdak S, Pickl WF, Selzer E, Deininger M, Druker BJ, Sillaber C, Estebauer H, Valent P. Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and re-expression by novel pharmacologic compounds. Cancer Res. 2005;65(20):9436-44. https://doi.org/10.1158/0008-5472.CAN-05-0972

100. Martinelli G, Mancini M, De Benedittis C, Rondoni M, Papayanni C, Manfrini M, Meggendorfer M, Calogero R, Guadagnuolo V, Fontana MC, Bavaro I, Padella A, Zago E, Pagano L, Zanotti R, Scaffidi L, Specchia G, Albano F, Merante S, Elena C, Savini P, Gangemi D, Tosi P, Ciceri F, Poletti G, Riccioni L, Morisi F, Delledonne M, Hafnerlach T, Cavo M, Valent P, Soverini S. SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis. Leukemia. 2018;32(1):139-148. https://doi.org/10.1038/leu.2017.183

101. Li J, Duns G, Westers H, Sijmons R, van den Berg A, Kok K. SETD2: an epigenetic modifier with tumor suppressor functionality. Onco-target. 2016;7(31):50719-50734. https://doi.org/10.18632/oncotarget.9368

102. Edmunds JW, Mahadevan LC, Clayton AL. Dynamic histone H3 methylation during gene induction: HYPB/Setd2 mediates all H3K36 trimethylation. EMBO J. 2008;27(2):406-20. https://doi.org/10.1016/j.cell.2016.07.005

103. Park IY, Powell RT, Tripathi DN, Dere R, Ho TH, Blasius TL, Chiang YC, Davis B, Fahey CC, Hacker KE, Verhey KJ, Bedford MT, Jonash E, Rathmell WK, Walker CL. Dual Chromatin and Cytoskeletal Remodeling by SETD2. Cell. 2016;166(4):950-962. https://doi.org/10.1016/j.cell.2016.07.005